29 06, 2018

Akathisia Induced by Abrupt Withdrawal of Risperidone: A Case Report

By | 2018-06-29T11:38:19+00:00 June 29th, 2018|Articles In Press|0 Comments

By Gangaparameswari Soundarrajan, Bharti Chogtu Magazine, Vybhav Krishna, Avinash Kamath G, and Manisha murugesan Abstract Akathisia is a common movement disorder that occurs as a consequence of antipsychotic therapy. However, its occurrence secondary to risperidone withdrawal has been reported rarely. Reporting of such rare adverse event gains profound importance because changing the antipsychotics is very [...]

29 06, 2018

Exercise as a Treatment for Schizophrenia: a Review

By | 2018-06-29T11:36:41+00:00 June 29th, 2018|Articles In Press|0 Comments

By Steven J. Girdler, Jamie E. Confino and Mary E. Woesner Abstract Schizophrenia is a mental disorder that is characterized by progressive cognitive impairment in areas of attention, working memory, and executive functioning. Although no clear etiology of schizophrenia has been discovered, many factors have been identified that contribute to the development [...]

29 06, 2018

Bipolar Medication, Lamictal, Linked with Serious Immune System Reaction

By | 2018-06-29T07:28:14+00:00 June 29th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

The Food and Drug Administration has issued a warning that the seizure and bipolar medication Lamictal (lamotrigine) can cause a rare but potentially life-threatening immune response. This life-threatening immune response, known as hemophagocytic lymphohistiocytosis (HLH), causes an uncontrolled immune response and can present as a persistent fever greater than 101° F. [...]

8 06, 2018

Effects of a depression-focused internet intervention in slot machine gamblers: A randomized controlled trial

By | 2018-06-08T16:28:40+00:00 June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

By Lara Bücker , Julia Bierbrodt, Iver Hand, Charlotte Wittekind, and Steffen Moritz Background Problematic and pathological gambling have been linked to depression. Despite a high demand for treatment and negative financial consequences, only a small fraction of problematic and pathological gamblers seek professional help. The existing treatment gap could be narrowed by providing [...]

8 06, 2018

Alzheimer’s Therapy Elenbecestat Reduces Brain Amyloid Levels, Trial Shows, but Decline of Clinical Symptoms Still a Question

By | 2018-06-08T08:10:58+00:00 June 8th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

Treatment with the investigational compound elenbecestat reduced brain amyloid beta levels and was safe and well-tolerated, according to Phase 2 clinical trial results. The presence of amyloid beta plaques is a major characteristic of the brains of Alzheimer’s disease patients. Amyloid beta is produced through the work of a key enzyme called [...]

6 06, 2018

Esketamine nasal spray prevails in phase 3 trials

By | 2018-06-06T07:29:40+00:00 June 6th, 2018|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

MIAMI — The combination of an esketamine nasal spray and an oral antidepressant may provide additional benefits for patients with treatment-resistant major depressive disorder, new research suggested. Two posters at a meeting of the American Society of Clinical Psychopharmacology, formerly known as the New Clinical Drug Evaluation Unit meeting, presented [...]

5 06, 2018

MDMA-Assisted Psychotherapy Improves PTSD

By | 2018-06-05T15:12:24+00:00 June 5th, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

MIAMI — Adding methylenedioxymethamphetamine (MDMA), also known as ecstasy, to intensive psychotherapy appears to relieve posttraumatic stress disorder (PTSD), regardless of the cause, pooled data from six phase 2 studies show. The findings were presented at the American Society of Clinical Psychopharmacology (ASCP) 2018 annual meeting. The pooled data from the [...]

5 06, 2018

Letter to the Editor: The Utilization of Atypical Antipsychotics in the Pain Medicine Physician’s Armamentarium

By | 2018-06-08T16:47:30+00:00 June 5th, 2018|Uncategorized|0 Comments

By Omar Viswanath MD Dear Editor, I read with great interest the recent article by Jimenez et al, A Systematic Review of Atypical Antipsychotics in Chronic Pain Management: Olanzapine Demonstrates Potential in Central Sensitization, Fibromyalgia, and Headache/Migraine. The article states “many psychopharmacologic agents are used as primary or adjuncts in pain [...]

1 06, 2018

An Alzheimer’s Antibiotic Receives Initial Funding

By | 2018-06-01T09:11:54+00:00 June 1st, 2018|Brief Bulletins from the Field, Featured, We Know Psychiatry|0 Comments

Alzheimer’s disease startup Cortexyme was able to round up $76 million in funding for a potentially first-in-class treatment, while other companies are looking to move away from the field, according to a posting today on FierceBiotech. The healthy sum comes after the company completed an early safety study of its [...]

24 05, 2018

Three-year Naturalistic Study On Early Use Of Long-acting Injectable Antipsychotics In First Episode Psychosis

By | 2018-06-08T16:47:33+00:00 May 24th, 2018|Uncategorized|0 Comments

By Sofia Medrano, Amal Abdel-Baki, Emmanuel Stip, and Stéphane Potvin Abstract Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psy- chosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these stud- ies represent a minority of patients [...]